BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 27173312)

  • 1. Inhibition of subcutaneously implanted human pituitary tumor cells in nude mice by LRIG1.
    Wang X; He XJ; Xu HQ; Chen ZW; Fan HH
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
    Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
    J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gene therapy study on bladder cancer with recombinant adenoviral vector carrying LRIG1 gene driven by Survivin promoter].
    Yan ZJ; Cheng Y; Jiang JH; Hu JS; Shi XD
    Zhonghua Wai Ke Za Zhi; 2012 Aug; 50(8):732-6. PubMed ID: 23157908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for LRIG1 in the regulation of malignant glioma aggressiveness.
    Mao F; Wang B; Xiao Q; Xi G; Sun W; Zhang H; Ye F; Wan F; Guo D; Lei T; Chen X
    Int J Oncol; 2013 Mar; 42(3):1081-7. PubMed ID: 23337938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [LRIG1 promotes the apoptosis of pituitary tumor cells induced by cisplatin].
    Zhou L; Bao C; Hu X; Dai Y; Bao Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jan; 34(1):9-15. PubMed ID: 29595451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways.
    Schulte SL; Waha A; Steiger B; Denkhaus D; Dörner E; Calaminus G; Leuschner I; Pietsch T
    Oncotarget; 2016 Aug; 7(34):55026-55042. PubMed ID: 27391150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
    Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
    Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
    Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
    Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the RAP1/RAF-1/extracellularly regulated kinase-1/2 cascade and prolactin release by the phosphoinositide 3-kinase/AKT pathway in pituitary cells.
    Romano D; Pertuit M; Rasolonjanahary R; Barnier JV; Magalon K; Enjalbert A; Gerard C
    Endocrinology; 2006 Dec; 147(12):6036-45. PubMed ID: 16935846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer.
    Kou C; Zhou T; Han X; Zhuang H; Qian H
    Biochem Biophys Res Commun; 2015 Aug; 464(2):519-25. PubMed ID: 26159916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
    Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A
    J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular mechanism of LRIG1 cDNA-induced apoptosis in human glioma cell line H4].
    Ye F; Guo DS; Niu HQ; Tao SZ; Ou YB; Lu YP; Lei T
    Ai Zheng; 2004 Oct; 23(10):1149-54. PubMed ID: 15473925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
    Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D
    PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
    McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
    J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.